Novo Nordisk Cuts Growth Forecast Amid Rising Pressure on Weight Loss Drug Prices

Danish pharma heavyweight Novo Nordisk (NASDAQ: NVO) revealed a more cautious stance toward its anticipated growth in obesity and diabetes medications this week. The company cited shifts in prescription trends, mounting rivalry, and squeezing pricing frameworks within the booming weight loss category.

In the latest quarter, Novo Nordisk booked a net profit of 20 billion Danish kroner ($3.1 billion), just meeting analyst expectations. Its blockbuster weight loss drug Wegovy posted sales of 20.35 billion kroner, which, despite an 18% year-over-year climb, fell slightly short of the 21.35 billion kroner analysts had forecast.

The stock took a hit at market open, dropping 4.5% before clawing back to a modest gain; it remains down nearly 45% so far this year as investor optimism wanes amid the company's revised outlook. Novo has trimmed its full-year sales growth forecast to 8-11% from the previous 8-14%, and operating profit growth expectations were narrowed to 4-7% from a prior 4-10% estimate.

CEO Mike Doustdar attributed the lowered guidance to a confluence of factors impacting their GLP-1 treatment franchise, including intensifying competition and pricing pressure. Roughly one-third of the U.S. obesity drug market, around one million patients, is now fiercely contested territory, he noted.

Analysts from UBS remain neutral despite the clouds on the horizon, having raised their price target after Novo announced a manageable impact from new U.S. drug pricing negotiations. The firm suspects price adjustments on Ozempic and Wegovy are a balancing act in play as Novo adapts to policy headwinds.

Beyond pricing and prescription dynamics, Novo's shares have been battered this year by a mix of disappointing clinical trial outcomes, leadership changes, and challenges tied to acquisitions and U.S. trade policies. While some analysts argue the company has reached 'peak uncertainty,' others highlight its strong R&D pipeline as a competitive edge.

Speaking of acquisitions, Novo is embroiled in a bidding war with Pfizer for U.S.-based biotech Metsera. The battle has spilled into courtroom skirmishes, with Pfizer accusing Novo of anticompetitive tactics-a charge Novo denies. Novo recently sweetened its offer to $10 billion, betting on bolstering its foothold in obesity treatments through Metsera's complementary drugs.

Doustdar emphasized the strategic importance of Metsera's portfolio to expand coverage of underserved patient populations. The company isn't shying away from taking on Pfizer in this contest, signaling a willingness to double down on growth even as pricing pressures mount.

With the obesity drug market evolving rapidly and policy environments shifting, Novo Nordisk's recalibrated outlook offers a rare glimpse into the challenges facing a former star performer now adjusting to a tougher playing field.